|
Agosti (1991)
|
USA
|
NA
|
3
|
Secondary/Tertiary Care
|
Non melancholic chro*c depression
|
6 weeks
|
Phenelzine 60-90mg
|
10
|
NA
|
NA
|
NA
|
Flexible
|
Oral
|
60mg to 90mg
|
NA
|
NA
|
|
Agosti (1991)
|
USA
|
NA
|
3
|
Secondary/Tertiary Care
|
Non melancholic chro*c depression
|
6 weeks
|
Placebo
|
23
|
NA
|
NA
|
NA
|
Flexible
|
Oral
|
NA
|
NA
|
NA
|
|
Agosti (1991)
|
USA
|
NA
|
3
|
Secondary/Tertiary Care
|
Non melancholic chro*c depression
|
6 weeks
|
Selegiline 40mg
|
12
|
NA
|
NA
|
NA
|
Fixed
|
Oral
|
40mg
|
40mg
|
NA
|
|
Amsterdam (1989)
|
USA
|
Sanofi Research (partial grant)
|
5
|
NA
|
Major depression
|
4 weeks
|
Minaprine 100mg
|
34
|
12
|
41
|
12
|
Flexible
|
Oral
|
100mg to 400mg
|
NA
|
93mg
|
|
Amsterdam (1989)
|
USA
|
Sanofi Research (partial grant)
|
5
|
NA
|
Major depression
|
4 weeks
|
Minaprine 200mg
|
39
|
25
|
37
|
13
|
Flexible
|
Oral
|
100mg to 400mg
|
NA
|
186mg
|
|
Amsterdam (1989)
|
USA
|
Sanofi Research (partial grant)
|
5
|
NA
|
Major depression
|
4 weeks
|
Minaprine 300mg
|
43
|
22
|
40
|
12
|
Flexible
|
Oral
|
100mg to 400mg
|
NA
|
279mg
|
|
Amsterdam (1989)
|
USA
|
Sanofi Research (partial grant)
|
5
|
NA
|
Major depression
|
4 weeks
|
Minaprine 400mg
|
37
|
22
|
37
|
13
|
Flexible
|
Oral
|
100mg to 400mg
|
NA
|
352mg
|
|
Amsterdam (1989)
|
USA
|
Sanofi Research (partial grant)
|
5
|
NA
|
Major depression
|
4 weeks
|
Placebo
|
37
|
18
|
39
|
13
|
NA
|
Oral
|
NA
|
NA
|
NA
|
|
Amsterdam (2003)
|
USA
|
Somerset Pharmaceuticals, Inc.
|
2
|
Secondary/Tertiary Care
|
Major depressive disorder, single or recurrent episode
|
8 weeks
|
Selegiline 20mg
|
149
|
94
|
41.2
|
11.6
|
Fixed
|
Transdermal
|
20mg
|
20mg
|
NA
|
|
Amsterdam (2003)
|
USA
|
Somerset Pharmaceuticals, Inc.
|
2
|
Secondary/Tertiary Care
|
Major depressive disorder, single or recurrent episode
|
8 weeks
|
Placebo
|
152
|
99
|
43.5
|
10
|
Fixed
|
Transdermal
|
NA
|
NA
|
NA
|
|
Bakish (1992)
|
Canada
|
NA
|
2
|
NA
|
Major depressive episode
|
6 weeks
|
Moclobemide up to 600mg
|
58
|
26
|
42
|
10.9
|
Flexible
|
Oral
|
NA to 600mg
|
NA to 600mg
|
492mg
|
|
Bakish (1992)
|
Canada
|
NA
|
2
|
NA
|
Major depressive episode
|
6 weeks
|
Placebo
|
56
|
20
|
44
|
10.7
|
Flexible
|
Oral
|
NA
|
NA
|
NA
|
|
Bellak (1966)
|
USA
|
*MH
|
2
|
Secondary/Tertiary Care
|
Depression
|
4 weeks
|
Placebo
|
25
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
|
Bellak (1966)
|
USA
|
*MH
|
2
|
Secondary/Tertiary Care
|
Depression
|
4 weeks
|
Phenelzine
|
25
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
|
Benes (2011)
|
Germany
|
GSK
|
2
|
NA
|
At least mild depressive symptoms
|
12 weeks
|
Placebo
|
67
|
45
|
59.5
|
11.3
|
Flexible to week 7, then fixed
|
Oral
|
NA
|
NA
|
NA
|
|
Benes (2011)
|
Germany
|
GSK
|
2
|
NA
|
At least mild depressive symptoms
|
12 weeks
|
Ropinirole 0.5-4mg
|
198
|
144
|
58.2
|
11.4
|
Flexible to week 7, then fixed
|
Oral
|
0.5 mg to 4 mg
|
NA
|
1.9 mg
|
|
Bodkin (2002)
|
NA
|
Somerset Pharmaceuticals
|
2
|
Secondary/Tertiary Care
|
Major depressive disorder, single or recurrent episode
|
6 weeks
|
Placebo
|
88
|
53
|
43.2
|
10.8
|
Fixed
|
Transdermal
|
NA
|
NA
|
NA
|
|
Bodkin (2002)
|
NA
|
Somerset Pharmaceuticals
|
2
|
Secondary/Tertiary Care
|
Major depressive disorder, single or recurrent episode
|
6 weeks
|
Selegiline 20mg
|
89
|
53
|
41.4
|
10.9
|
Fixed
|
Transdermal
|
20mg
|
20mg
|
20mg
|
|
Botte (1992)
|
NA
|
NA
|
2
|
NA
|
Unipolar depression, neurotic depression
|
6 weeks
|
Placebo
|
24
|
16
|
43.33
|
9.9
|
NA
|
NA
|
NA
|
NA
|
NA
|
|
Botte (1992)
|
NA
|
NA
|
2
|
NA
|
Unipolar depression, neurotic depression
|
6 weeks
|
Moclobemide 300-600mg
|
23
|
13
|
51.39
|
12.69
|
Flexible
|
Oral
|
300mg to 600mg
|
200mg to 600mg
|
NA
|
|
Bymaster (2011)
|
Romania, Serbia, USA
|
DOV Pharmaceuticals, Euthymics Bioscience
|
2
|
Secondary/Tertiary Care
|
Depressive disorder
|
6 weeks
|
Placebo
|
29
|
19
|
49.5
|
6.9
|
Fixed
|
Oral
|
NA
|
NA
|
NA
|
|
Bymaster (2011)
|
Romania, Serbia, USA
|
DOV Pharmaceuticals, Euthymics Bioscience
|
2
|
Secondary/Tertiary Care
|
Depressive disorder
|
6 weeks
|
Amitifadine 50mg
|
34
|
25
|
48.2
|
9.4
|
Fixed
|
Oral
|
50mg to 50mg
|
25mg to 50mg
|
NA
|
|
Casacchia (1984)
|
Italy
|
NA
|
2
|
Secondary/Tertiary Care
|
Unipolar psychotic depression, neurotic depression
|
4 weeks
|
Moclobemide 150-450 mg
|
18
|
8
|
49.5
|
12.8
|
Flexible
|
Oral
|
NA
|
150mg to 450mg
|
297.2mg
|
|
Casacchia (1984)
|
Italy
|
NA
|
2
|
Secondary/Tertiary Care
|
Unipolar psychotic depression, neurotic depression
|
4 weeks
|
Placebo
|
16
|
11
|
49
|
11.4
|
Flexible
|
Oral
|
NA
|
150mg to 400mg
|
212.5mg
|
|
Chouinard (1993)
|
Canada, UK
|
NA
|
2
|
Secondary/Tertiary Care
|
Major depressive episode
|
6 weeks
|
Placebo
|
109
|
66
|
40.200000000000003
|
18-64 (range)
|
Fixed
|
Oral
|
NA
|
NA
|
NA
|
|
Chouinard (1993)
|
Canada, UK
|
NA
|
2
|
Secondary/Tertiary Care
|
Major depressive episode
|
6 weeks
|
Brofaromine 75-100mg
|
111
|
57
|
41.2
|
18-64 (range)
|
Fixed
|
Oral
|
75mg to 150mg
|
NA
|
NA
|
|
Clayton (2006a)
|
USA
|
Glaxo Wellcome Inc.
|
2
|
Secondary/Tertiary Care
|
Major Depressive Disorder
|
8 weeks
|
Bupropion
|
141
|
85
|
36.5
|
12.2
|
Flexible
|
Oral
|
300mg to 450mg
|
300mg to 450mg
|
323mg
|
|
Clayton (2006a)
|
USA
|
Glaxo Wellcome Inc.
|
2
|
Secondary/Tertiary Care
|
Major Depressive Disorder
|
8 weeks
|
Placebo
|
141
|
88
|
35.1
|
11.8
|
Flexible
|
Oral
|
NA
|
NA
|
NA
|
|
Clayton (2006b)
|
USA
|
Glaxo Wellcome Inc.
|
2
|
Secondary/Tertiary Care
|
Major Depressive Disorder
|
8 weeks
|
Bupropion
|
138
|
76
|
37
|
12.5
|
Flexible
|
Oral
|
300mg to 450mg
|
300mg to 450mg
|
309mg
|
|
Clayton (2006b)
|
USA
|
Glaxo Wellcome Inc.
|
2
|
Secondary/Tertiary Care
|
Major Depressive Disorder
|
9 weeks
|
Placebo
|
137
|
76
|
37
|
10.7
|
Flexible
|
Oral
|
NA
|
NA
|
NA
|
|
Coleman (1999)
|
USA
|
Glaxo Wellcome Inc.
|
2
|
NA
|
Moderate to severe depression
|
8 weeks
|
Placebo
|
124
|
73
|
38.5
|
18-65 (range)
|
Flexible
|
Oral
|
NA
|
NA
|
NA
|
|
Coleman (1999)
|
USA
|
Glaxo Wellcome Inc.
|
2
|
NA
|
Moderate to severe depression
|
8 weeks
|
Bupropion SR 150-400mg
|
122
|
68
|
38.1
|
18-64 (range)
|
Flexible
|
Oral
|
150mg to 400mg
|
100mg to 365mg
|
290mg
|
|
Coleman (1999)
|
USA
|
Glaxo Wellcome Inc.
|
2
|
NA
|
Moderate to severe depression
|
8 weeks
|
Placebo
|
152
|
92
|
36.700000000000003
|
19-62 (range)
|
Flexible
|
Oral
|
NA
|
NA
|
NA
|
|
Coleman (1999)
|
USA
|
Glaxo Wellcome Inc.
|
2
|
NA
|
Moderate to severe depression
|
8 weeks
|
Bupropion 150-400mg
|
150
|
95
|
36.6
|
18-67 (range)
|
Flexible
|
Oral
|
150mg to 400mg
|
NA
|
NA
|
|
Corrigan (2000)
|
USA
|
NA
|
4
|
NA
|
Major depression, single episode or recurrent episode
|
8 weeks
|
Placebo
|
35
|
NA
|
NA
|
NA
|
Fixed
|
Oral
|
NA
|
NA
|
NA
|
|
Corrigan (2000)
|
USA
|
NA
|
4
|
NA
|
Major depression, single episode or recurrent episode
|
8 weeks
|
Pramipexole 0.375mg
|
36
|
NA
|
NA
|
NA
|
Fixed
|
Oral
|
0.375mg
|
0.375mg
|
0.375mg
|
|
Corrigan (2000)
|
USA
|
NA
|
4
|
NA
|
Major depression, single episode or recurrent episode
|
8 weeks
|
Pramipexole 1mg
|
35
|
NA
|
NA
|
NA
|
Fixed
|
Oral
|
1mg
|
1mg
|
1mg
|
|
Corrigan (2000)
|
USA
|
NA
|
4
|
NA
|
Major depression, single episode or recurrent episode
|
8 weeks
|
Pramipexole 5mg
|
33
|
NA
|
NA
|
NA
|
Fixed
|
Oral
|
5mg
|
5mg
|
5mg
|
|
Croft (1999)
|
NA
|
Glaxo Wellcome Inc.
|
2
|
NA
|
Moderate to severe depression
|
8 weeks
|
Placebo
|
121
|
61
|
37.4
|
19-64 (range)
|
Flexible
|
Oral
|
NA
|
NA
|
NA
|
|
Croft (1999)
|
NA
|
Glaxo Wellcome Inc.
|
2
|
NA
|
Moderate to severe depression
|
8 weeks
|
Bupropion SR 150-400mg
|
120
|
61
|
35.9
|
19-70 (range)
|
Flexible
|
Oral
|
150mg to 400mg
|
127mg to 361mg
|
293mg
|
|
Davidson (1988)
|
NA
|
Hoffmann La Roche
|
2
|
NA
|
Major or minor depression
|
6 weeks
|
Isocarboxazid
|
68
|
37
|
41.9
|
NA
|
Flexible
|
Oral
|
NA
|
NA
|
49.3mg
|
|
Davidson (1988)
|
NA
|
Hoffmann La Roche
|
2
|
NA
|
Major or minor depression
|
6 weeks
|
Placebo
|
62
|
35
|
41.9
|
NA
|
Flexible
|
Oral
|
NA
|
NA
|
NA
|
|
DelBello (2014)
|
USA
|
Somerset Pharmaceutical, Inc.
|
2
|
Secondary/Tertiary Care
|
Moderate or severe Major Depressive Disorder
|
12 weeks
|
Placebo
|
156
|
104
|
14.7
|
1.6
|
Flexible
|
Transdermal
|
NA
|
NA
|
NA
|
|
DelBello (2014)
|
USA
|
Somerset Pharmaceutical, Inc.
|
2
|
Secondary/Tertiary Care
|
Moderate or severe Major Depressive Disorder
|
12 weeks
|
Selegiline 6-12mg
|
152
|
93
|
14.8
|
1.62
|
Flexible
|
Transdermal
|
6mg to 12mg
|
NA
|
NA
|
|
Feiger (2006)
|
USA
|
Somerset Pharmaceutical, Inc.
|
2
|
NA
|
Moderate or severe Major Depressive Disorder
|
8 weeks
|
Selegiline 6-12mg
|
132
|
81
|
42
|
NA
|
Flexible
|
Transdermal
|
6mg to 12mg
|
6mg to 12mg
|
NA
|
|
Feiger (2006)
|
USA
|
Somerset Pharmaceutical, Inc.
|
2
|
NA
|
Moderate or severe Major Depressive Disorder
|
8 weeks
|
Placebo
|
133
|
71
|
42
|
NA
|
Flexible
|
Transdermal
|
NA
|
NA
|
NA
|
|
Feighner (1984)
|
NA
|
NA
|
2
|
Secondary/Tertiary Care
|
Major depressive disorder
|
4 weeks
|
Placebo
|
22
|
19
|
49
|
22-78 (range)
|
NA
|
Oral
|
NA
|
NA
|
NA
|
|
Feighner (1984)
|
NA
|
NA
|
2
|
Secondary/Tertiary Care
|
Major depressive disorder
|
4 weeks
|
Bupropion up to 600mg
|
44
|
30
|
43.9
|
20-70 (range)
|
Flexible
|
Oral
|
NA to 600mg
|
300mg to 600mg
|
392mg
|
|
Georgotas (1986)
|
USA
|
NAMH
|
2
|
NA
|
Major depressive disorder
|
7 weeks
|
Placebo
|
28
|
15
|
64.7
|
7.6
|
Flexible
|
Oral
|
NA
|
NA
|
NA
|
|
Georgotas (1986)
|
USA
|
NAMH
|
2
|
NA
|
Major depressive disorder
|
7 weeks
|
Phenelzine
|
22
|
13
|
65.5
|
4.4000000000000004
|
Flexible
|
Oral
|
NA
|
NA
|
53.90mg
|
|
Giller (1982)
|
USA
|
NAMH, Hoffman-LaRoche
|
2
|
Secondary/Tertiary Care
|
Depression
|
6 weeks
|
Placebo
|
NA
|
NA
|
NA
|
NA
|
Flexible
|
Oral
|
NA
|
NA
|
73mg
|
|
Giller (1982)
|
USA
|
NAMH, Hoffman-LaRoche
|
2
|
Secondary/Tertiary Care
|
Depression
|
6 weeks
|
Isocarboxazid
|
NA
|
NA
|
NA
|
NA
|
Flexible
|
Oral
|
NA
|
NA
|
48mg
|
|
GlaxoSmithKline (1980)
|
USA
|
GSK
|
3
|
Community
|
Major depressive disorder
|
6 weeks
|
Bupropion 150-450mg
|
52
|
35
|
36.4
|
21-67 (range)
|
Flexible
|
Oral
|
150mg to 450mg
|
NA
|
NA
|
|
GlaxoSmithKline (1980)
|
USA
|
GSK
|
3
|
Community
|
Major depressive disorder
|
6 weeks
|
Bupropion 300-900mg
|
23
|
13
|
37.799999999999898
|
21-62 (range)
|
Flexible
|
NA
|
300mg to 900mg
|
NA
|
NA
|
|
GlaxoSmithKline (1980)
|
USA
|
GSK
|
3
|
Community
|
Major depressive disorder
|
6 weeks
|
Placebo
|
47
|
31
|
37.4
|
21-60 (range)
|
Flexible
|
Oral
|
NA
|
NA
|
NA
|
|
GlaxoSmithKline (1985)
|
USA, Canada
|
GSK
|
3
|
Secondary/Tertiary Care
|
Depressive disorder
|
4 weeks
|
Placebo
|
43
|
20
|
51.9
|
25-78 (range)
|
Fixed
|
Oral
|
NA
|
NA
|
NA
|
|
GlaxoSmithKline (1985)
|
USA, Canada
|
GSK
|
3
|
Secondary/Tertiary Care
|
Depressive disorder
|
4 weeks
|
Bupropion 300mg
|
45
|
18
|
52.4
|
26-80 (range)
|
Fixed
|
Oral
|
300mg
|
300mg
|
NA
|
|
GlaxoSmithKline (1985)
|
USA, Canada
|
GSK
|
3
|
Secondary/Tertiary Care
|
Depressive disorder
|
4 weeks
|
Bupropion 450mg
|
40
|
18
|
47.5
|
20-73 (range)
|
Fixed
|
Oral
|
450mg
|
450mg
|
NA
|
|
GlaxoSmithKline (1993)
|
USA
|
GSK
|
5
|
NA
|
NA
|
8 weeks
|
Placebo
|
124
|
80
|
40.700000000000003
|
11.6
|
NA
|
NA
|
NA
|
NA
|
NA
|
|
GlaxoSmithKline (1993)
|
USA
|
GSK
|
5
|
NA
|
NA
|
8 weeks
|
Bupropion SR 100mg
|
119
|
77
|
39.6
|
11.9
|
Fixed
|
NA
|
100mg
|
NA
|
NA
|
|
GlaxoSmithKline (1993)
|
USA
|
GSK
|
5
|
NA
|
NA
|
8 weeks
|
Bupropion SR 200mg
|
120
|
65
|
39.6
|
10.4
|
Fixed
|
NA
|
200mg
|
NA
|
NA
|
|
GlaxoSmithKline (1993)
|
USA
|
GSK
|
5
|
NA
|
NA
|
8 weeks
|
Bupropion SR 300mg
|
120
|
70
|
39.9
|
11.4
|
Fixed
|
NA
|
300mg
|
NA
|
NA
|
|
GlaxoSmithKline (1993)
|
USA
|
GSK
|
5
|
NA
|
NA
|
8 weeks
|
Bupropion SR 400mg
|
119
|
66
|
38.799999999999898
|
11.7
|
Fixed
|
NA
|
400mg
|
NA
|
NA
|
|
GlaxoSmithKline (1994)
|
USA
|
GSK
|
3
|
Secondary/Tertiary Care
|
Major depressive disorder
|
8 weeks
|
Bupropion 50-150mg
|
152
|
90
|
39.1
|
12.2
|
Flexible
|
Oral
|
50mg to 150mg
|
50mg to 150mg
|
NA
|
|
GlaxoSmithKline (1994)
|
USA
|
GSK
|
3
|
Secondary/Tertiary Care
|
Major depressive disorder
|
8 weeks
|
Placebo
|
154
|
99
|
38.200000000000003
|
11.4
|
NA
|
Oral
|
NA
|
NA
|
NA
|
|
GlaxoSmithKline (1994)
|
USA
|
GSK
|
3
|
Secondary/Tertiary Care
|
Major depressive disorder
|
8 weeks
|
Bupropion 100-300mg
|
150
|
98
|
37.200000000000003
|
11.3
|
Flexible
|
Oral
|
100mg to 300mg
|
100mg to 300mg
|
NA
|
|
Han (2012)
|
South Korea
|
Korea Research Foundation Grant
|
2
|
Community
|
MDD and problematic online game play
|
8 weeks
|
Placebo
|
28
|
0
|
18.100000000000001
|
6.2
|
NA
|
NA
|
NA
|
NA
|
NA
|
|
Han (2012)
|
South Korea
|
Korea Research Foundation Grant
|
2
|
Community
|
MDD and problematic online game play
|
8 weeks
|
Bupropion 150-300mg
|
29
|
0
|
21.2
|
8
|
Fixed
|
Oral
|
150mg to 300mg
|
NA
|
NA
|
|
Hewett (2009)
|
Austria, Belgium, Bulgaria, Croatia, Estonia, Finland, Greece, Ireland,
Latvia, Netherlands, Poland, Portugal, Russia, Slovakia, Spain, Sweden
and Mexico
|
GSK
|
2
|
NA
|
Major depressive disorder
|
8 weeks
|
Placebo
|
199
|
142
|
41.8
|
11.56
|
Flexible
|
Oral
|
NA
|
NA
|
NA
|
|
Hewett (2009)
|
Austria, Belgium, Bulgaria, Croatia, Estonia, Finland, Greece, Ireland,
Latvia, Netherlands, Poland, Portugal, Russia, Slovakia, Spain, Sweden
and Mexico
|
GSK
|
2
|
NA
|
Major depressive disorder
|
8 weeks
|
Bupropion XR 150-300mg
|
188
|
138
|
41.8
|
11.68
|
Flexible
|
Oral
|
150mg to 300mg
|
NA
|
170.1mg
|
|
Hewett (2010a)
|
Australia, France, Germany, the Netherlands, Norway, South Africa and
Sweden
|
GSK
|
2
|
NA
|
Major depressive disorder
|
8 weeks
|
Placebo
|
189
|
125
|
44.5
|
10.79
|
Flexible
|
Oral
|
NA
|
NA
|
NA
|
|
Hewett (2010a)
|
Australia, France, Germany, the Netherlands, Norway, South Africa and
Sweden
|
GSK
|
2
|
NA
|
Major depressive disorder
|
8 weeks
|
Bupropion XR 150-300mg
|
204
|
127
|
45.6
|
11.76
|
Flexible
|
Oral
|
150mg to 300mg
|
150mg to 300mg
|
180mg
|
|
Hewett (2010b)
|
Australia, Belgium, Canada, Croatia, Finland, France, Germany, India,
Latvia, Netherlands, Norway, Poland, Republic of South Africa, Russia
and United States
|
GSK
|
2
|
NA
|
Major depressive disorder
|
10 weeks
|
Placebo
|
207
|
144
|
71.3
|
5.9
|
Flexible
|
Oral
|
NA
|
NA
|
NA
|
|
Hewett (2010b)
|
Australia, Belgium, Canada, Croatia, Finland, France, Germany, India,
Latvia, Netherlands, Norway, Poland, Republic of South Africa, Russia
and United States
|
GSK
|
2
|
NA
|
Major depressive disorder
|
10 weeks
|
Bupropion XR 150-300mg
|
211
|
157
|
70.900000000000006
|
5.6
|
Flexible
|
Oral
|
150mg to 300mg
|
150mg to 300mg
|
NA
|
|
Iosifescu (2022)
|
USA
|
Xsome Therapeutics
|
2
|
NA
|
Major depressive disorder
|
6 weeks
|
Dextromethorphan + Bupropion
|
156
|
95
|
42.1
|
12.8
|
NA
|
Oral
|
45mg to 105mg
|
NA
|
NA
|
|
Iosifescu (2022)
|
USA
|
Xsome Therapeutics
|
2
|
NA
|
Major depressive disorder
|
6 weeks
|
Placebo
|
162
|
117
|
41.2
|
13.77
|
NA
|
Oral
|
NA
|
NA
|
NA
|
|
Jarrett (1999)
|
NA
|
NA
|
2
|
Community
|
Major depressive disorder, atypical features
|
10 weeks
|
Phenelzine 0.85-1mg/kg
|
36
|
25
|
38.700000000000003
|
9.7799999999999905
|
NA
|
NA
|
0.85mg/kg to 1mg/kg
|
NA
|
64mg
|
|
Jarrett (1999)
|
NA
|
NA
|
2
|
Community
|
Major depressive disorder, atypical features
|
10 weeks
|
Placebo
|
36
|
22
|
40.299999999999898
|
10.08
|
NA
|
NA
|
NA
|
NA
|
NA
|
|
Jefferson (2006)
|
NA
|
GSK
|
2
|
NA
|
Major depressive disorder
|
8 weeks
|
Placebo
|
139
|
96
|
39.799999999999997
|
16-69 (range)
|
Flexible
|
Oral
|
NA
|
NA
|
NA
|
|
Jefferson (2006)
|
NA
|
GSK
|
2
|
NA
|
Major depressive disorder
|
8 weeks
|
Bupropion XR 150-450mg
|
135
|
89
|
40
|
20-68 (range)
|
Flexible
|
Oral
|
150mg to 450mg
|
150mg to 450mg
|
NA
|
|
Koshino (2013)
|
Japan, South Korea
|
GSK
|
3
|
NA
|
Major depressive disorder
|
10 weeks
|
Placebo
|
186
|
85
|
37.9
|
11.09
|
Fixed
|
Oral
|
NA
|
NA
|
NA
|
|
Koshino (2013)
|
Japan, South Korea
|
GSK
|
3
|
NA
|
Major depressive disorder
|
10 weeks
|
Bupropion 150mg
|
190
|
92
|
36
|
10.42
|
Fixed
|
Oral
|
150mg
|
150mg
|
NA
|
|
Koshino (2013)
|
Japan, South Korea
|
GSK
|
3
|
NA
|
Major depressive disorder
|
10 weeks
|
Bupropion 300mg
|
188
|
83
|
37.5
|
10.96
|
Fixed
|
Oral
|
300mg
|
300mg
|
NA
|
|
Kusalic (1993)
|
NA
|
NA
|
2
|
NA
|
Major depressive episode
|
6 weeks
|
Placebo
|
9
|
NA
|
NA
|
NA
|
Flexible
|
Oral
|
NA
|
NA
|
NA
|
|
Kusalic (1993)
|
NA
|
NA
|
2
|
NA
|
Major depressive episode
|
6 weeks
|
Moclobemide
|
11
|
NA
|
NA
|
NA
|
Flexible
|
Oral
|
NA
|
NA
|
482.60mg
|
|
Larsen (1989)
|
Denmark
|
NA
|
2
|
Secondary/Tertiary Care
|
Major depressive episode
|
6 weeks
|
Placebo
|
18
|
12
|
57
|
25-76 (range)
|
Flexible
|
Oral
|
NA
|
NA
|
NA
|
|
Larsen (1989)
|
Denmark
|
NA
|
2
|
Secondary/Tertiary Care
|
Major depressive episode
|
6 weeks
|
Moclobemide up to 300mg
|
22
|
15
|
51
|
28-70 (range)
|
Flexible
|
Oral
|
NA to 300mg
|
NA to 300mg
|
NA
|
|
Learned (2012a)
|
Australia, Belgium, Bulgaria, Canada, Estonia, Finland, France, Germany,
India, Poland, Slovakia, and South Africa
|
GSK
|
2
|
NA
|
Major depressive disorder
|
10 weeks
|
Placebo
|
126
|
46
|
41.9
|
11.79
|
Fixed
|
Oral
|
NA
|
NA
|
NA
|
|
Learned (2012a)
|
Australia, Belgium, Bulgaria, Canada, Estonia, Finland, France, Germany,
India, Poland, Slovakia, and South Africa
|
GSK
|
2
|
NA
|
Major depressive disorder
|
10 weeks
|
GSK372475 1.5-2mg
|
134
|
51
|
43
|
12.07
|
Fixed
|
Oral
|
1.5mg to 2mg
|
1mg to 2mg
|
NA
|
|
Learned (2012b)
|
Bulgaria, Canada, Chile, Costa Rica, Croatia, France, Germany, India,
Italy, and Poland
|
GSK
|
2
|
NA
|
Major depressive disorder
|
10 weeks
|
Placebo
|
156
|
39
|
41.8
|
10.89
|
Fixed
|
Oral
|
NA
|
NA
|
NA
|
|
Learned (2012b)
|
Bulgaria, Canada, Chile, Costa Rica, Croatia, France, Germany, India,
Italy, and Poland
|
GSK
|
2
|
NA
|
Major depressive disorder
|
10 weeks
|
GSK372475 1-1.5mg
|
171
|
54
|
42.4
|
11.64
|
Fixed
|
Oral
|
1mg to 1.5mg
|
1mg to 1.5mg
|
NA
|
|
Liebowitz (1984)
|
NA
|
Public Health Service
|
2
|
Community
|
Atypical depression
|
6 weeks
|
Placebo
|
24
|
14
|
37.700000000000003
|
8.9
|
Flexible
|
Oral
|
NA
|
NA
|
NA
|
|
Liebowitz (1984)
|
NA
|
Public Health Service
|
2
|
Community
|
Atypical depression
|
6 weeks
|
Phenelzine 15-90mg
|
15
|
7
|
33.799999999999898
|
9.3000000000000007
|
Flexible
|
Oral
|
15mg to 90mg
|
60mg to 90mg
|
74mg
|
|
Mann (1989)
|
USA
|
Irma Hirschl and Mallinckrodt Foundations
|
2
|
Secondary/Tertiary Care
|
Major depressive episode
|
6 weeks
|
Placebo
|
22
|
17
|
40.200000000000003
|
10.7
|
Flexible
|
NA
|
NA
|
NA
|
NA
|
|
Mann (1989)
|
USA
|
Irma Hirschl and Mallinckrodt Foundations
|
2
|
Secondary/Tertiary Care
|
Major depressive episode
|
6 weeks
|
Selegiline up to 50mg
|
22
|
16
|
45.2
|
12.3
|
Flexible
|
Oral
|
NA
|
NA to 50mg
|
NA
|
|
Nair (1995)
|
Canada, Denmark, UK
|
NA
|
2
|
Secondary/Tertiary Care
|
Major depressive episode
|
7 weeks
|
Moclobemide 400mg
|
36
|
25
|
67 (median)
|
60-90 (range)
|
Fixed
|
Oral
|
400mg
|
400mg
|
NA
|
|
Nair (1995)
|
Canada, Denmark, UK
|
NA
|
2
|
Secondary/Tertiary Care
|
Major depressive episode
|
7 weeks
|
Placebo
|
35
|
25
|
71 (median)
|
62-89 (range)
|
Fixed
|
Oral
|
NA
|
NA
|
NA
|
|
Ose (1992)
|
NA
|
NA
|
2
|
NA
|
Major depressive episode
|
4 weeks
|
Moclobemide 300-500mg
|
35
|
21
|
49 (median)
|
24-79 (range)
|
Fixed
|
Oral
|
300mg to 500mg
|
300mg to 500mg
|
NA
|
|
Ose (1992)
|
NA
|
NA
|
2
|
NA
|
Major depressive episode
|
4 weeks
|
Placebo
|
33
|
18
|
50 (median)
|
30-72 (range)
|
Fixed
|
Oral
|
NA
|
NA
|
NA
|
|
Parnetti (1993)
|
Italy
|
Gruppo Sanofi
|
2
|
Secondary/Tertiary Care
|
Prolonged depressive reaction
|
12 weeks
|
Minapramine 200mg
|
63
|
36
|
71.599999999999895
|
6.5
|
Fixed
|
Oral
|
200mg
|
200mg
|
200mg
|
|
Parnetti (1993)
|
Italy
|
Gruppo Sanofi
|
2
|
Secondary/Tertiary Care
|
Prolonged depressive reaction
|
12 weeks
|
Placebo
|
67
|
47
|
71.3
|
6.6
|
Fixed
|
Oral
|
NA
|
NA
|
NA
|
|
Quitkin (1990)
|
USA
|
*MH; NHCRC
|
2
|
NA
|
Major, minor, or intermittent depression
|
6 weeks
|
Phenelzine 90mg
|
33
|
NA
|
38.9
|
NA
|
Fixed
|
Oral
|
90mg
|
45mg to 90mg
|
NA
|
|
Quitkin (1990)
|
USA
|
*MH; NHCRC
|
2
|
NA
|
Major, minor, or intermittent depression
|
6 weeks
|
Placebo
|
34
|
NA
|
30.1
|
NA
|
Fixed
|
Oral
|
NA
|
NA
|
NA
|
|
Raft (1981)
|
USA
|
*H
|
2
|
Secondary/Tertiary Care
|
Depression
|
5 weeks
|
Phenelzine 90mg
|
NA
|
NA
|
NA
|
NA
|
Fixed
|
Oral
|
90mg
|
30mg to 90mg
|
90mg
|
|
Raft (1981)
|
USA
|
*H
|
2
|
Secondary/Tertiary Care
|
Depression
|
5 weeks
|
Placebo
|
NA
|
NA
|
NA
|
NA
|
Fixed
|
Oral
|
NA
|
NA
|
NA
|
|
Rampello (1991)
|
Italy
|
NA
|
2
|
Secondary/Tertiary Care
|
Primary major u*polar depression or bipolar affective disorder depressed
|
6 weeks
|
Minaprine 100mg
|
10
|
NA
|
NA
|
NA
|
Fixed
|
Oral
|
100mg
|
100mg to 200mg
|
NA
|
|
Rampello (1991)
|
Italy
|
NA
|
2
|
Secondary/Tertiary Care
|
Primary major u*polar depression or bipolar affective disorder depressed
|
6 weeks
|
Placebo
|
10
|
NA
|
NA
|
NA
|
Fixed
|
Oral
|
NA
|
NA
|
NA
|
|
Raskin (1972)
|
USA
|
*MH
|
2
|
Secondary/Tertiary Care
|
Depression
|
5 weeks
|
Placebo
|
111
|
NA
|
NA
|
NA
|
Fixed
|
Oral
|
NA
|
NA
|
NA
|
|
Raskin (1972)
|
USA
|
*MH
|
2
|
Secondary/Tertiary Care
|
Depression
|
5 weeks
|
Phenelzine 45mg
|
110
|
72
|
37 (median)
|
NA
|
Fixed
|
Oral
|
45mg
|
22.5mg to 45mg
|
NA
|
|
Ravaris (1976)
|
NA
|
Public Health Service; Warner Lambert Research Institute
|
3
|
Primary care
|
Depression
|
6 weeks
|
Phenelzine 60mg
|
21
|
NA
|
43.1
|
15.12
|
NA
|
Oral
|
60mg
|
60mg
|
NA
|
|
Ravaris (1976)
|
NA
|
Public Health Service; Warner Lambert Research Institute
|
3
|
Primary care
|
Depression
|
6 weeks
|
Phenelzine 30mg
|
21
|
NA
|
41.2
|
16.5
|
Fixed
|
Oral
|
30mg
|
30mg
|
NA
|
|
Ravaris (1976)
|
NA
|
Public Health Service; Warner Lambert Research Institute
|
3
|
Primary care
|
Depression
|
6 weeks
|
Placebo
|
21
|
NA
|
38.9
|
10.1
|
Fixed
|
Oral
|
NA
|
NA
|
NA
|
|
Reimherr (1998)
|
USA
|
Glaxo Wellcome Inc.
|
3
|
NA
|
Major depression
|
8 weeks
|
Placebo
|
121
|
69
|
40.200000000000003
|
12.2
|
Fixed
|
Oral
|
NA
|
NA
|
NA
|
|
Reimherr (1998)
|
USA
|
Glaxo Wellcome Inc.
|
3
|
NA
|
Major depression
|
8 weeks
|
Bupropion SR 150mg
|
121
|
86
|
38.299999999999997
|
11
|
Fixed
|
Oral
|
150mg
|
150mg
|
NA
|
|
Reimherr (1998)
|
USA
|
Glaxo Wellcome Inc.
|
3
|
NA
|
Major depression
|
8 weeks
|
Bupropion SR 300mg
|
120
|
92
|
38.6
|
10.7
|
Fixed
|
Oral
|
300mg
|
300mg
|
NA
|
|
Rickels (1970)
|
USA
|
Public Health Service
|
2
|
Community, Primary care, Secondary/Tertiary Care
|
Moderate depression
|
4 weeks
|
Methylphenidate 15mg
|
NA
|
NA
|
NA
|
NA
|
Fixed
|
Oral
|
15mg
|
15mg
|
NA
|
|
Rickels (1970)
|
USA
|
Public Health Service
|
2
|
Community, Primary care, Secondary/Tertiary Care
|
Moderate depression
|
4 weeks
|
Placebo
|
NA
|
NA
|
NA
|
NA
|
Fixed
|
Oral
|
NA
|
NA
|
NA
|
|
Riesenberg (2010)
|
USA
|
Rexahn Pharmaceuticals
|
4
|
NA
|
Major depression
|
8 weeks
|
Placebo
|
21
|
11
|
42.5
|
10.8
|
Fixed
|
Oral
|
NA
|
NA
|
NA
|
|
Riesenberg (2010)
|
USA
|
Rexahn Pharmaceuticals
|
4
|
NA
|
Major depression
|
8 weeks
|
RX-10100 5mg
|
21
|
11
|
44.8
|
11.9
|
Fixed
|
Oral
|
5mg
|
5mg
|
NA
|
|
Riesenberg (2010)
|
USA
|
Rexahn Pharmaceuticals
|
4
|
NA
|
Major depression
|
8 weeks
|
RX-10100 10mg
|
16
|
7
|
42.6
|
11.97
|
Fixed
|
Oral
|
10mg
|
10mg
|
NA
|
|
Riesenberg (2010)
|
USA
|
Rexahn Pharmaceuticals
|
4
|
NA
|
Major depression
|
8 weeks
|
RX-10100 15mg
|
17
|
9
|
39.4
|
11.27
|
Fixed
|
Oral
|
15mg
|
15mg
|
NA
|
|
Robin (1958)
|
UK
|
NA
|
2
|
Secondary/Tertiary Care
|
Depression
|
4 weeks
|
Placebo
|
23
|
13
|
39.5
|
13.9
|
Flexible
|
Oral
|
NA
|
NA
|
NA
|
|
Robin (1958)
|
UK
|
NA
|
2
|
Secondary/Tertiary Care
|
Depression
|
4 weeks
|
Methylphenidate 20-40mg
|
22
|
16
|
37.5
|
11.5
|
Flexible
|
Oral
|
20mg to 40mg
|
NA
|
NA
|
|
Rowan (1980)
|
NA
|
NA
|
2
|
Secondary/Tertiary Care
|
Depression or mixed anxiety/depression
|
6 weeks
|
Phenelzine 45-75mg
|
NA
|
NA
|
NA
|
NA
|
Flexible
|
Oral
|
45mg to 75mg
|
NA
|
NA
|
|
Rowan (1980)
|
NA
|
NA
|
2
|
Secondary/Tertiary Care
|
Depression or mixed anxiety/depression
|
6 weeks
|
Placebo
|
NA
|
NA
|
NA
|
NA
|
Fixed
|
Oral
|
NA
|
NA
|
NA
|
|
Tomarken (2004)
|
USA
|
Glaxo Wellcome Inc.
|
2
|
Community
|
Major depression
|
6 weeks
|
Bupropion SR 300-400mg
|
10
|
6
|
39.4
|
9.8
|
Fixed
|
Oral
|
300mg to 400mg
|
100mg to 400mg
|
NA
|
|
Tomarken (2004)
|
USA
|
Glaxo Wellcome Inc.
|
2
|
Community
|
Major depression
|
6 weeks
|
Placebo
|
9
|
6
|
37.5
|
7.8
|
Fixed
|
Oral
|
NA
|
NA
|
NA
|
|
Ucha (1990)
|
NA
|
NA
|
2
|
NA
|
Major depression
|
6 weeks
|
Placebo
|
24
|
13
|
42.2
|
15.1
|
Flexible
|
Oral
|
NA
|
NA
|
5.6 tabs per day
|
|
Ucha (1990)
|
NA
|
NA
|
2
|
NA
|
Major depression
|
6 weeks
|
Moclobemide 300-600mg
|
24
|
16
|
40.5
|
15.6
|
Flexible
|
Oral
|
300mg to 600mg
|
NA
|
405mg
|
|
UK Moclobomide Study Group (1994)
|
UK
|
NA
|
2
|
NA
|
Major depressive episode
|
6 weeks
|
Placebo
|
54
|
NA
|
NA
|
NA
|
Fixed
|
Oral
|
NA
|
NA
|
NA
|
|
UK Moclobomide Study Group (1994)
|
UK
|
NA
|
2
|
NA
|
Major depressive episode
|
6 weeks
|
Moclobemide 450mg
|
56
|
NA
|
NA
|
NA
|
Fixed
|
Oral
|
450mg
|
450mg
|
NA
|
|
Versiani (1989)
|
NA
|
NA
|
2
|
NA
|
Major depression
|
6 weeks
|
Moclobemide 300-600mg
|
164
|
124
|
44
|
12
|
Flexible
|
Oral
|
300mg to 600mg
|
NA
|
NA
|
|
Versiani (1989)
|
NA
|
NA
|
2
|
NA
|
Major depression
|
6 weeks
|
Placebo
|
162
|
123
|
42
|
12
|
Flexible
|
Oral
|
NA
|
NA
|
NA
|
|
Versiani (1990)
|
Brazil
|
NA
|
2
|
NA
|
Major depression
|
6 weeks
|
Moclobemide 600mg
|
25
|
NA
|
NA
|
NA
|
NA
|
Oral
|
600mg
|
600mg
|
600mg
|
|
Versiani (1990)
|
Brazil
|
NA
|
2
|
NA
|
Major depression
|
6 weeks
|
Placebo
|
25
|
NA
|
NA
|
NA
|
NA
|
Oral
|
NA
|
NA
|
NA
|
|
Versiani (1997)
|
NA
|
NA
|
2
|
Secondary/Tertiary Care
|
Dysthymia
|
6 weeks
|
Moclobemide 75-750mg
|
108
|
73
|
41
|
12
|
Flexible
|
Oral
|
75mg to 750mg
|
75mg to 750mg
|
633mg
|
|
Versiani (1997)
|
NA
|
NA
|
2
|
Secondary/Tertiary Care
|
Dysthymia
|
6 weeks
|
Placebo
|
104
|
71
|
40
|
11
|
Flexible
|
Oral
|
NA
|
NA
|
NA
|
|
White (1984)
|
USA
|
NA
|
2
|
Secondary/Tertiary Care
|
Major depression
|
4 weeks
|
Tranylcypromine 30-60mg
|
63
|
14
|
38
|
NA
|
Flexible
|
Oral
|
30mg to 60mg
|
NA
|
44.4mg
|
|
White (1984)
|
USA
|
NA
|
2
|
Secondary/Tertiary Care
|
Major depression
|
4 weeks
|
Placebo
|
59
|
21
|
39
|
NA
|
Flexible
|
Oral
|
NA
|
NA
|
NA
|
|
Zarate (2006)
|
NA
|
NA
|
2
|
Secondary/Tertiary Care
|
Major depression
|
8 weeks
|
Memantine 5-20mg
|
16
|
9
|
47.1
|
12.3
|
Flexible
|
Oral
|
5mg to 20mg
|
5mg to 20mg
|
19.4mg
|
|
Zarate (2006)
|
NA
|
NA
|
2
|
Secondary/Tertiary Care
|
Major depression
|
8 weeks
|
Placebo
|
16
|
7
|
46.1
|
9.4
|
Flexible
|
Oral
|
NA
|
NA
|
NA
|
|
Zisook (1985)
|
NA
|
NA
|
2
|
Secondary/Tertiary Care
|
Major or minor depression
|
6 weeks
|
Isocarboxazid up to 80mg
|
NA
|
NA
|
NA
|
NA
|
Flexible
|
Oral
|
NA to 80mg
|
NA
|
39.00mg
|
|
Zisook (1985)
|
NA
|
NA
|
2
|
Secondary/Tertiary Care
|
Major or minor depression
|
6 weeks
|
Placebo
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|
NA
|